{
    "clinical_study": {
        "@rank": "90657", 
        "arm_group": {
            "arm_group_label": "RAD001", 
            "arm_group_type": "Experimental", 
            "description": "RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days."
        }, 
        "brief_summary": {
            "textblock": "This trial intends to test the efficacy and safety of RAD001 in patients with advanced\n      sarcoma who failed to conventional chemotherapy."
        }, 
        "brief_title": "RAD001 in Advanced Sarcoma", 
        "condition": [
            "Soft Tissue Sarcomas", 
            "Bone Sarcomas"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteosarcoma", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This multicenter, phase II trial evaluated the efficacy and safety of everolimus in patients\n      with metastatic or recurrent bone and soft tissue sarcoma after failure of anthracycline\n      and/or ifosfamide."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically confirmed metastatic, unresectable bone or soft tissue\n             sarcomas who had past treatment with anthracycline and/or ifosfamide to which the\n             disease was primarily refractory or progressed after initial response.\n\n          -  Any of above drugs is allowed to be used as adjuvant treatment.\n\n          -  Unidimensionally measurable disease\n\n          -  3 or less than prior chemotherapies\n\n          -  Age 17 years old or older\n\n          -  ECOG performance status 2 or less, Life expectancy 6 month or less\n\n          -  Adequate bone marrow, liver, kidney, and cardiac function\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating patients\n\n          -  Patients with resectable metastasis\n\n          -  Patients with history of CNS metastasis\n\n          -  Gastrointestinal stromal tumors, chondrosarcoma, neuroblastoma\n\n          -  Hypersensitivity to the active substance, to other rapamycin derivatives, or to any\n             of the excipients.\n\n          -  Any preexisting medical condition of sufficient severity to prevent full compliance\n             with the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830153", 
            "org_study_id": "CRAD001CKR13T"
        }, 
        "intervention": {
            "arm_group_label": "RAD001", 
            "intervention_name": "RAD001", 
            "intervention_type": "Drug", 
            "other_name": "Everolimus"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Soft tissue sarcomas", 
            "Bone sarcomas", 
            "RAD001", 
            "Refractory to conventional chemotherapy"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi", 
                        "zip": "463-707"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "N/A = Not Applicable", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center, University of Ulsan College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yeongnam University College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-721"
                    }, 
                    "name": "Chungnam National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "126-1"
                    }, 
                    "name": "Korea University"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas", 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Jin-Hee Ahn, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Determined as the proportion of progression-free (complete response, partial response and stable disease) at 16 weeks of treatment", 
            "measure": "Progression-free survival rate at 16 weeks", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "reference": [
            {
                "PMID": "8315424", 
                "citation": "Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269-75."
            }, 
            {
                "PMID": "10811673", 
                "citation": "Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, Seynaeve C, di Paola ED, van Glabbeke M, Tonelli D, Judson IR. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000 May;18(10):2081-6."
            }, 
            {
                "PMID": "15631540", 
                "citation": "Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs. 2005;65(2):167-78. Review."
            }, 
            {
                "PMID": "7602342", 
                "citation": "Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45."
            }, 
            {
                "PMID": "10894866", 
                "citation": "Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676-84."
            }, 
            {
                "PMID": "12460784", 
                "citation": "van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J; EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397-406."
            }, 
            {
                "PMID": "16107623", 
                "citation": "Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005 Aug 18;353(7):701-11. Review. No abstract available."
            }, 
            {
                "PMID": "17766661", 
                "citation": "Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007 Aug;12(8):1007-18. Review."
            }, 
            {
                "PMID": "18653228", 
                "citation": "Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Gr\u00fcnwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. Epub 2008 Jul 22."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830153"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Jin-Hee Ahn", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined as the time from the initiation of everolimus to disease progression or death, whichever occurred first.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Defined from the initiation of everolimus to death of any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Defined as the proportion of complete response and partial response per RECIST criteria.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Any adverse events occurred during the treatment with study drug.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}